Remote Electrophysiological Cardiotocography (eCTG) Feasibility in Complicated Pregnancies From 32 to 37 Weeks Gestation Using Home@Hospital Monitoring

What this Trial Is About

Researchers are evaluating the feasibility of using remote electrophysiological cardiotocography (eCTG) monitoring for women with complicated pregnancies between 32 and 37 weeks of gestation. This study aims to assess the success rate of self-administered eCTG measurements along with maternal and perinatal outcomes, patient and healthcare professional satisfaction, and antenatal costs. The study is a single-center, interventional cohort trial focused on remote monitoring in a home and hospital setting. Participants will use the Nemo Remoteae device to perform daily self-administered eCTG monitoring for 30 to 90 minutes in a Home@Hospital setting or at least twice weekly at the outpatient clinic. Alongside eCTG monitoring, participants will self-measure their blood pressure, heart rate, and temperature, and enter these data along with symptoms and concerns into a smartphone application. The study period includes monitoring from inclusion until 37 weeks of gestational age or delivery if earlier. During the study, participants will complete questionnaires at three different times to assess their wellbeing and satisfaction with the remote monitoring and overall care. Researchers will track the number of successful eCTG measurements, changes in monitoring methods, maternal and neonatal health outcomes, and healthcare costs. The study includes follow-up for maternal and neonatal conditions up to six weeks post-delivery, ensuring comprehensive observation of safety and effectiveness measures throughout pregnancy and after childbirth.

Feasibility of Remote eCTG Monitoring Home@Hospital in Complicated Pregnancies